Tuyen Ong

Dr. Ong is a Physician, Bioentrepreneur and Ring's CEO. Prior to joining Ring Therapeutics, Dr. Ong served as Senior Vice President at Biogen. Previously, Dr. Ong served as Chief Development Officer at Nightstar Therapeutics up until its acquisition by Biogen. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, investor, and M&A activities. Dr. Ong brings over 20 years of clinical and drug development experience from both large pharma and biotech, working in the fields of genetic, ophthalmology, and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer.